Experience with high dose methotrexate therapy in childhood acute lymphoblastic leukemia in a tertiary care cancer centre of a developing country

Pediatric Blood and Cancer

Volumn 59, Issue 3, 2012, Pages 448-453

  Kapoor, Gauri ^a   Sinha, Rupal ^a   Abedin, Sarfraz ^a  

^a RAJIV GANDHI CANCER INSTITUTE AND RESEARCH CENTRE   (India)

Author keywords

Childhood acute lymphoblastic leukemia; High dose methotrexate; Toxicity

Indexed keywords

FOLINIC ACID; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BLOOD TOXICITY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONSOLIDATION CHEMOTHERAPY; CONTROLLED STUDY; DEVELOPING COUNTRY; DRUG FEVER; DRUG MEGADOSE; EVENT FREE SURVIVAL; FEMALE; FLUID INTAKE; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERTRANSAMINASEMIA; IMMUNOPHENOTYPING; INFANT; KIDNEY FUNCTION; LENGTH OF STAY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIVER FUNCTION; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RADIATION DOSE; RECURRENCE FREE SURVIVAL; RELATIVE DENSITY; RETROSPECTIVE STUDY; SCHOOL CHILD; SKULL IRRADIATION; TERTIARY HEALTH CARE; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; URINE PH; URINE VOLUME;

ANTIMETABOLITES, ANTINEOPLASTIC; CANCER CARE FACILITIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INJECTIONS, SPINAL; LEUCOVORIN; MALE; METHOTREXATE; MUCOSITIS; NEUTROPENIA; PATIENT READMISSION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RETROSPECTIVE STUDIES;

EID: 84863869277     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24081     Document Type: Article

References (47)

1. Pui CH, Relling MV, Pharm D, et al. Mechanisms of disease acute lymphoblastic leukemia. N Engl J Med 2004; 350: 1535-1548.
2. Evans AE, Gilbert ES, Zandstra R. The increasing incidence of central nervous system leukemia in children. Cancer 1970; 26: 404-409.
3. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
4. Ochs J, Mulhern R. Long-term sequelae of therapy for childhood acute lymphoblastic leukemia. Baillieres Clin Haematol 1994; 7: 365-376.
5. Clayton PE, Shalet SM, Morris-Jones PH, et al. Growth in children treated for acute lymphoblastic leukemia. Lancet 1988; 1: 460-462.
6. Cousens P, Waters B, Said J, et al. Cognitive effects of cranial irradiation in leukaemia: A survey and meta-analysis. J Child Psychol Psychiatry 1988; 29: 839-852.
7. Jankovic M, Brouwers P, Valsecchi MG, et al. Association of 1800cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukemia. ISPACC. International study group on psychosocial aspects of childhood cancer. Lancet 1994; 344: 224-227.
8. Silber JH, Radcliffe J, Peckham V, et al. Whole-brain irradiation and decline in intelligence: The influence of dose and age on IQ score. J Clin Oncol 1992; 10: 1390-1396.
9. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109: 896-904.
10. Hill FG, Richards S, Gibson B, et al. Successful treatment without cranial radiotherapy of children receiving intensified chemotherapy for acute lymphoblastic leukemia: Results of the risk-stratified randomized central nervous system treatment trial MRC UKALL XI (ISRC TN 16757172). Br J Haematol 2004; 124: 33-46.
11. Moricke A, Reiter A, Zimmermann M, et al. Risk adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: Treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. Blood 2008; 111: 4477-4489.
12. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Leukemia 2000; 14: 2205-2222.
13. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000; 14: 2247-2256.
14. Pui CH, Boyett JM, Rivera GK, et al. Long-term results of Total Therapy studies 11, 12 and 13A for childhood acute lymphoblastic leukemia at St Jude Children's Research Hospital. Leukemia 2000; 14: 2286-2294.
15. Niemann A, Mühlisch J, Frühwald MC, et al. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: Can the burden of intrathecal methotrexate be reduced? Ther Drug Monit 2010; 32: 467-475.
16. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Washington: DC, 2003.
17. Abedin S, Kapoor G. Peripherally inserted central venous catheters are a good option for prolonged venous access in children with cancer. Pediatr Blood Cancer 2008; 51: 251-255.
18. Raje NS, Vaidya SJ, Kapoor G, et al. Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia. Indian Pediatr 1996; 33: 556-560.
19. Smith M, Bleyer A, Crist W, et al. Uniform criteria for childhood acute lymphoblastic leukemia risk classification. J Clin Oncol 1996; 14: 680-681.
20. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
21. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol 2008; 9: 257-268.
22. Clarke M, Gaynon P, Hann I, et al. CNS-Directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL collaborative group overview of 43 randomized trials. J Clin Oncol 2003; 21: 1798-1809.
23. Mantadakis E, Cole PD, Kamen BA. High dose methotrexate in acute lymphoblastic leukemia: Where is the evidence for its continued use? Pharmacotherapy 2005; 25: 748-755.
24. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long term results of the Children's Cancer Group Studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group report. Leukemia 2010; 24: 285-297.
25. Matloub Y, Bostrom BC, Hunger SP, et al. Escalating dose intravenous methotrexate without leukovorin rescue during interim maintenance is superior to oral methotrexate for children with standard risk acute lymphoblastic leukemia (SR-ALL): A Children's Concology Group Study 1991. Blood 2008; 112: 9-10a.
26. Arya LS. Acute lymphoblastic leukemia: Current treatment concepts. Indian Pediatr 2000; 37: 397-406.
27. Bhatt K, Sharma I, Kapoor G. Evaluation of administration of high dose methotrexate by nurses in a pediatric hematology oncology unit in Delhi (abstract). Pediatr Blood Cancer 2007; 49: 556.
28. Martelli N, Mathieu O, Margueritte G, et al. Methotrexate pharmacokinetics in childhood acute lymphoblastic leukaemia: A prognostic value? J Clin Pharm Ther 2011; 36: 237-245.
29. Crom WR, Evans WE. Methotrexate. In: Evans WE, Schentag JJ, Jusko WJ, editors. Applied pharmacokinetics. Principles of therapeutic drug monitoring, 3rd edition. Spokane, WA: 1992. 29-31.
30. Christensen ML, Rivera GK, Crom WR, et al. Effect of hydration on methotrexate plasma concentration in children with acute lymphoblastic leukemia. J Clin Oncol 1988; 6: 797-801.
31. Sasaki K, Tanaka J, Murakami T, et al. Reduced citrovorum factor rescue for high-dose methotrexate therapy in childhood malignancies. Cancer Drug Deliv 1985; 2: 77-86.
32. Moore MJ, Erlichman C. Therapeutic drug monitoring in oncology: Problems and potential in antineoplastic therapy. Clin Pharmacokinet 1987; 13: 205-227.
33. Kishi S, Cheng C, French D, et al. Ancestry and pharmacogenetics of antileukemic drug toxicity. Blood 2007; 109: 4151-4157.
34. Rask C, Albertioni F, Bentzen SM, et al. Clinical and pharmacokinetic risk factors for high-dose methotrexate-induced toxicity in children with acute lymphoblastic leukemia: A logistic regression analysis. Acta Oncologica 1998; 37: 277-284.
35. Rask C, Albertioni F, Schroder H, et al. Oral mucositis in children with acute lymphoblastic leukemia after high-dose methotrexate treatment without delayed elimination of methotrexate: Relation to pharmacokinetic parameters of methotrexate. Pediatr Hematol Oncol 1996; 13: 359-367.
36. Albertioni F, Rask C, Schroeder H, et al. Monitoring of methotrexate and 7-hydroxymethotrexate in saliva from children with acute lymphoblastic leukemia receiving high-dose consolidation treatment: Relation to oral mucositis. Anticancer Drugs 1997; 8: 119-124.
37. Ishii E, Yamada S, Higuchi S, et al. Oral mucositis and salivary methotrexate concentration in intermediate-dose methotrexate therapy for children with acute lymphoblastic leukemia. Med Pediatr Oncol 1989; 17: 429-432.
38. Weber BL, Tanyer G, Poplack DG, et al. Transient acute hepatotoxicity of high-dose methotrexate therapy during childhood. NCI Monogr 1987; 5: 207-212.
39. Kinoshita A, Kurosawa Y, Kondoh K, et al. Effects of sodium in hydration solution on plasma methotrexate concentrations following high-dose methotrexate in children with acute lymphoblastic leukemia. Cancer Chemother Pharmacol 2003; 51: 256-260.
40. Borsi JD, Csáki C, Paál C, et al. Toxicity of high-dose methotrexate therapy. In: Riccardi R, Borsi J, editors. The role of clinical pharmacology in pediatric oncology, San Francisco: 6th Pharmacology Workshop Satellite to XXV SIOP Meeting, 1993. 112-118.
41. Sterba J, Valik D, Bajciova V, et al. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: Do we really know why, when and how? Neoplasma 2005; 52: 456-463.
42. Nirenberg A, Mosende C, Mehta BM, et al. High-dose methotrexate with citrovorum factor rescue: Predictive value of plasma methotrexate concentration and corrective measures to avert toxicity. Cancer Treat Rep 1977; 61: 779-783.
43. Kapoor G, Maitra A, Somlata Brahmachari V. Application of SNaPshot for analysis of thiopurine methyltransferase gene polymorphism. Indian J Med Res 2009; 129: 500-505.
44. Kapoor G, Sinha R, Naithani R, Chandgothia M. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. Leuk Res 2010; 34: 1023-1026.
45. Keefe DM, Rassias G, O'Neil L, et al. Severe mucositis: How can nutrition help? Curr Opin Clin Nutr Metab Care 2007; 10: 627-631.
46. Schrappe M, Reiter A, Ludwig WD, et al. Improved outcome in childhood ALL despite reduced use of anthracyclines and of cranial radiotherapy: Results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM study group. Blood. 2000; 95: 3310-3322.
47. Conter V, Arico M, Valsecchi MG, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in intermediate-risk ALL children treated with BFM-based intensive chemotherapy. The Associazione Italiana di Ematologia ed Oncologia Pediatrica. J Clin Oncol 1995; 13: 2497-2502.